Search for Terms or Answers
The ACR journal, Arthritis & Rheumatology, has publish a listing of top articles in 2021 as measured by Altmetric, an online service that tracks what gets "clicked" and discussed. Interestingly, this includes 4 guidelines and 5 COVID-related papers.
Concerns about the long-term safety of hydroxychloroquine (HCQ) often results in dose reduction or drug discontinuation; yet a current study shows that, for those in remission, HCQ taper/discontinuation resulted in a significantly higher rate of SLE flares.
A recent prospective, randomized, blinded clinical trial has shown that a 2 week hold of methotrexate (MTX) following COVID-19 (Sinovac-CoronaVac) vaccination resulted in greater anti-SARS-CoV-2 immunogenicity; but there was an increase in flare rates after the second dose of vaccine.
MMWR has reported the results of the National Football Leagues (NFL) change in SARS-CoV-2 testing program that went into effect in December 2021, at the height of the Omicron variant surge, showing that among those with asymptomatic infection, only half were PCR test negative and could return to
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, rheumatologic problems incited by respiratory infections, air pollution and how you live, now where you live.
Guselkumab, an IL-2319-subunit antibody, was studied in active psoriatic arthritis (PsA) patients who had a previously inadequate response (IR) to tumour necrosis factor inhibitors (TNFi) and after 1 year was shown to significantly improved joint and skin manifestations and physical function.
The American College of Rheumatology (ACR) is launching two new initiatives to reduce racial disparities in lupus clinical trials: Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY) and new Continuing Medical Educatio
Data from the European Alliance of Associations for Rheumatology Coronavirus Vaccine registry shows that patients with with inflammatory or noninflammatory rheumatic and musculoskeletal disease have similar adverse event rates as the general public.
The annual Medscape Physician Burnout & Depression survey has been published for 2022 and Rheumatology burnout stats have improved, now ranking 10th (middle of the pack).
MMWR has published the results of the 2017 Behavioral Risk Factor Surveillance System showing that increases in the number of social risk factors independently increases the odds of arthritis and its burden in the USA.
A pragmatic, open-label trial of osteoarthritis (OA) patients demonstrated that adding duloxetine treatment seems to be beneficial for end-stage knee OA patients with neuropathic-like symptoms (at risk of central sensitization).
Drs. Jack Cush and Artie Kavanaugh review the highlights of the RWCS (Rheumatology Winter Clinical Symposium) from Maui.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
